-
August 9, 2018 •
Bio-Pharma, Clinical Trials, Feature Slider, Feature-Home, Featured-Slides-Home •
280
Milestone Pharmaceuticals, a clinical-stage cardiovascular company, has randomised the first patient in its Phase 3 clinical...
-
April 24, 2018 •
Bio-Pharma, Feature Slider, Feature-Home, Featured-Slides-Home, Uncategorized •
300
Vancouver-based Zymeworks Inc., a biopharmaceutical company, and the biotech giant Celgene Corporation announce that they have...
-
November 29, 2017 •
Bio-Pharma, Business Focus, Feature, Feature Slider, Feature-Home, Featured-Slides-Home •
483
There are many reasons that Mississauga has become an exceptional place to set up shop in the life sciences community. So many in...
-
April 27, 2017 •
Bio-Pharma, Drug Development, Feature Slider, Featured-Slides-Home, Policy/Regulatory/IP, Science Focus •
375
An estimated 100,000 people living in Canada are suffering from multiple sclerosis – that is the highest ratio of MS...
-
April 26, 2017 •
Bio-Pharma, Business Focus, Clinical Trials, Feature Slider, Featured-Slides-Home, Management Updates •
250
Montreal-based biotechnology company InSymbiosis is collaborating with Jupiter Orphan Therapeutics Inc.(JOT) in managing the...
-
April 14, 2014 •
Bio-Pharma, Feature, Pharmacogenomics, Science Focus •
3437
From 1997 to 2010, despite promises made by the international scientific community, pharmacogenomic research produced few studies...
-
April 14, 2014 •
Bio-Pharma, Business Focus, Management Updates •
1868
Dalton Medicinal Chemistry has received notice that the award from the National Institute On Drug Abuse (NIDA) to research and...
-
March 28, 2014 •
Bio-Pharma, Business Focus, Deals/M&A/Collaboration •
1998
Cardiome Pharma Corp. has entered into a distribution agreement with Logista Pharma S.A., headquartered in Madrid, Spain, to...
-
March 11, 2014 •
Bio-Pharma, Business Focus, Capital markets/Funding •
1985
Aquinox Pharmaceuticals, Inc. has announced the pricing of its initial public offering of 4,200,000 shares. The common stock will...
-
March 3, 2014 •
Bio-Pharma, Drug Development, Science Focus •
2062
Genome BC’s Proof-of-Concept funding program is helping to develop a new vaccine for one of the most widespread sexually...